These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 4425889)

  • 1. Gross impairment of hepatic drug metabolism in a patient with chronic liver disease.
    Adjepon-Yamoah KK; Nimmo J; Prescott LF
    Br Med J; 1974 Nov; 4(5941):387-8. PubMed ID: 4425889
    [No Abstract]   [Full Text] [Related]  

  • 2. Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease.
    Forrest JA; Finlayson ND; Adjepon-Yamoah KK; Prescott LF
    Br Med J; 1977 May; 1(6073):1384-7. PubMed ID: 861646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipyrine and lidocaine are cleared faster in horses than in humans: acetaminophen may be handled similarly.
    Engelking LR; Lofstedt J; Blyden GT; Greenblatt DJ
    Pharmacology; 1987; 34(4):192-200. PubMed ID: 3602088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug metabolism in liver disease. Identification of patients with impaired hepatic drug metabolism.
    Farrell GC; Cooksley WG; Hart P; Powell LW
    Gastroenterology; 1978 Oct; 75(4):580-8. PubMed ID: 710827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug metabolism in patients with liver disease (author's transl)].
    Richter E; Epping J; Fuchshofen-Röckel M; Heusler H; Zilly W
    Leber Magen Darm; 1980 Oct; 10(5):234-40. PubMed ID: 7464410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug disposition in patients with HBsAg-positive chronic liver disease.
    Villeneuve JP; Thibeault MJ; Ampelas M; Fortunet-Fouin H; LaMarre L; Côté J; Pomier-Layrargues G; Huet PM
    Dig Dis Sci; 1987 Jul; 32(7):710-4. PubMed ID: 3595383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Changes in metabolic function of the liver in patients with chronic hepatic diseases].
    Kupcová V; Holomán J; Turecký L; Ulicná O; Brixová E
    Bratisl Lek Listy; 1985 Jan; 83(1):35-40. PubMed ID: 3967146
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pharmacometabolic capacity of the liver and the effect of pancreozymin in chronic hepatitis, chronic pancreatitis and diabetes mellitus].
    Geller LI; Griaznova MV; Bulgakova OS; Kozlova ZP
    Ter Arkh; 1982; 54(2):67-9. PubMed ID: 7071776
    [No Abstract]   [Full Text] [Related]  

  • 9. Altered elimination of antipyrine in patients with acute viral hepatitis.
    Burnett DA; Barak AJ; Tuma DJ; Sorrell MF
    Gut; 1976 May; 17(5):341-4. PubMed ID: 1278717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of chlorpromazine on drug metabolism.
    Stevenson IH; O'Malley K; Turnbull MJ; Ballinger BR
    J Pharm Pharmacol; 1972 Jul; 24(7):577-8. PubMed ID: 4403852
    [No Abstract]   [Full Text] [Related]  

  • 11. Proceedings: Antipyrine, lingocaine and paracetamol metabolism in chronic liver disease.
    Forrest JA; Finlayson ND; Adjepon-Yamoah KK; Prescott LF
    Gut; 1975 Oct; 16(10):828-9. PubMed ID: 1205294
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug metabolism in liver disease.
    Prescott LF; Forrest JA; Adjepon-Yamoah KK; Finlayson ND
    J Clin Pathol Suppl (R Coll Pathol); 1975; 9():62-5. PubMed ID: 783214
    [No Abstract]   [Full Text] [Related]  

  • 13. Spironolactone--a weak enzyme inducer in man.
    Taylor SA; Rawlins MD; Smith SE
    J Pharm Pharmacol; 1972 Jul; 24(7):578-9. PubMed ID: 4403853
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of portacaval shunt on the disposition of drugs with and without first-pass effect.
    Gugler R; Lain P; Azarnoff DL
    J Pharmacol Exp Ther; 1975 Dec; 195(3):416-23. PubMed ID: 1195128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced drug metabolism in cigarette smokers.
    Hart P; Farrell GC; Cooksley WG; Powell LW
    Br Med J; 1976 Jul; 2(6028):147-9. PubMed ID: 1276835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of inflammation on the metabolism of antipyrine, lidocaine and propranolol in isolated rat hepatocytes.
    Chindavijak B; Belpaire FM; Bogaert MG
    Pharmacology; 1988; 36(4):279-82. PubMed ID: 3380881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis.
    Shiffman ML; Luketic VA; Sanyal AJ; Duckworth PF; Purdum PP; Contos MJ; Mills AS; Edinboro LE; Poklis A
    Hepatology; 1994 Apr; 19(4):933-40. PubMed ID: 8138268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impairment of hepatic drug metabolism in patients with acute viral hepatitis.
    Narang AP; Datta DV; Nath N; Mathur VS
    Eur J Drug Metab Pharmacokinet; 1982; 7(4):255-8. PubMed ID: 7166177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of serum antipyrine half-lives in patients with liver disease.
    Branch RA; Herbert CM; Read AE
    Gut; 1973 Jul; 14(7):569-73. PubMed ID: 4729926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of flurbiprofen on the metabolism of antipyrine in man.
    Chalmers IM; Bell MA; Buchanan WW
    Ann Rheum Dis; 1973 Jan; 32(1):58-61. PubMed ID: 4539857
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.